The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Yuki Matsubara
Honoraria - Bristol Myers Squibb; Lilly Japan; Taiho Pharmaceutical; Takeda
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Kazuaki Harada
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshiaki Mihara
Honoraria - Chugai Pharma; Sanofi; Taiho Pharmaceutical
 
Izuma Nakayama
No Relationships to Disclose
 
Naoki Izawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kissei Pharmaceutical; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Kawakami
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Hiroko Hasegawa
No Relationships to Disclose
 
Takashi Ohta
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Takeda
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)